Vessel Normalization in the Spot-LIGHT of Cancer Treatment
Manuel Ehling1, Massimiliano Mazzone1
1Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, B3000 Leuven, Belgium; Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, Department of Oncology, KU Leuven, B3000 Leuven, Belgium.
Abstract:
Targeting the aberrant, nonfunctional tumor vasculature is one of the most promising approaches of new anticancer therapies. Here, we discuss a recent publication and a novel mechanism by which tumor-associated macrophages can actively induce vessel normalization and junction stability, and improve the distribution of therapeutic drugs into a tumor.
Insights
Tumor-associated macrophages can normalize abnormal tumor blood vessels, improving drug delivery. This discovery offers a promising new strategy for anticancer therapies by targeting nonfunctional tumor vasculature.
Area of Science:
- Oncology
- Immunology
- Vascular Biology
Background:
- Aberrant tumor vasculature is a significant challenge in cancer therapy.
- Nonfunctional tumor blood vessels hinder drug distribution and treatment efficacy.
Purpose of the Study:
- To discuss a novel mechanism involving tumor-associated macrophages (TAMs).
- To highlight how TAMs can induce tumor vessel normalization and junction stability.
Main Methods:
- Review of a recent publication detailing TAM-mediated vascular effects.
- Analysis of the molecular mechanisms underlying TAM-induced vessel normalization.
Main Results:
- TAMs actively promote the normalization of tumor vasculature.
- Enhanced vessel stability leads to improved therapeutic drug distribution within tumors.
Conclusions:
- Targeting TAMs represents a promising strategy for improving anticancer therapies.
- Vessel normalization by TAMs can overcome drug delivery barriers in solid tumors.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...